Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBD)

Details for Australian Patent Application No. 2011206532 (hide)

Owner Institut Pasteur Institut National de la Recherche Agronomique (INRA) Universite Paris Diderot - Paris 7 INSERM (Institut National de la Sante et de la Recherche Medicale)

Inventors Vergnolle, Nathalie; Sallenave, JeanMichel; Langella, Philippe; Bermudez-Humaran, Luis

Agent Spruson & Ferguson

Pub. Number AU-A-2011206532

PCT Pub. Number WO2011/086172

Priority 10305045.6 14.01.10 EP

Filing date 14 January 2011

Wipo publication date 21 July 2011

International Classifications

C07K 14/81 Peptides having more than 20 amino acids - Protease inhibitors

A61K 35/74 Medicinal preparations containing material or reaction products thereof with undetermined constitution

C12N 15/74 Mutation or genetic engineering - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

C12R 1/225

Event Publications

19 July 2012 PCT application entered the National Phase

  PCT publication WO2011/086172 Priority application(s): WO2011/086172

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011206534-Diagnostic gene expression platform

2011206524-CVD single crystal diamond material